BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28869613)

  • 1. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
    Modi D; Deol A; Kim S; Ayash L; Alavi A; Ventimiglia M; Bhutani D; Ratanatharathorn V; Uberti JP
    Bone Marrow Transplant; 2017 Nov; 52(11):1530-1536. PubMed ID: 28869613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD34
    Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
    Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
    Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
    Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
    Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
    McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
    J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
    Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
    Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).
    Pohlen M; Groth C; Sauer T; Görlich D; Mesters R; Schliemann C; Lenz G; Müller-Tidow C; Büchner T; Berdel WE; Stelljes M
    Bone Marrow Transplant; 2016 Nov; 51(11):1441-1448. PubMed ID: 27295269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.
    Tamari R; Chung SS; Papadopoulos EB; Jakubowski AA; Hilden P; Devlin SM; Goldberg JD; Perales MA; Ponce DM; Sauter CS; Maloy MA; Herman DY; Klimek V; Young JW; O'Reilly RJ; Giralt SA; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2106-2114. PubMed ID: 26187863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
    Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
    J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
    Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
    Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V
    Bone Marrow Transplant; 2015 Sep; 50(9):1180-6. PubMed ID: 26121109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
    Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
    J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
    Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
    Zhang ZH; Lian XY; Yao DM; He PF; Ma JC; Xu ZJ; Guo H; Zhang W; Lin J; Qian J
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1853-1864. PubMed ID: 28470473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.